Administration of DAB389IL-2 to patients with recalcitrant psoriasis: A double-blind, phase II multicenter trial

This publication has 10 references indexed in Scilit:

• Systemic Tacrolimus (FK 506) Is Effective for the Treatment of Psoriasis in a Double-blind, Placebo-Controlled Study
  Archives of Dermatology, 1996
• Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
  Nature Medicine, 1995
• Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
  Clinical and Experimental Dermatology, 1994
• Effects of administration of an anti‐cd5 plus immunoconjugate in rheumatoid arthritis. results of two phase ii studies
  Arthritis & Rheumatism, 1993
• Cloning of the γ Chain of the Human IL-2 Receptor
  Science, 1992
• Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis
  The Lancet, 1991
• Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells.
  Journal of Biological Chemistry, 1990
• The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis
  British Journal of Dermatology, 1987
• Intracellular pathway of interleukin 2 following receptor‐mediated endocytosis
  European Journal of Immunology, 1986
• Severe Psoriasis – Oral Therapy with a New Retinoid
  Dermatology, 1978